explore -WSS

explore

author：explore 2025-09-28 19:19:15 - browse：5

Miniature people figurines standing in a group looking down. -- health tech coverage from STAT — Adobe

In less than two years, digital health’s high-flying class of public debuts have landed with a resounding thud.

Accelerated by the pandemic’s forced adoption of telehealth and other digital health solutions, 2021 saw more than 30 health technology startups go public, raising hundreds of millions and in some cases billions of dollars. Today, three members of the class of 2021 have gone bankrupt. Twelve companies have lost more than 90% of their initial value, including Bright Health Group, Cue Health, and Better Therapeutics. And dangerously low reserves have inspired desperate moves to slash costs, drum up liquidity, and find buyers.

Most recently, the bankruptcy of digital primary care company Babylon Health has drawn attention to the plight of newly-public health tech companies, and how the froth of dealmaking at the height of the pandemic led to overblown valuations. Before its debut in June 2021, Babylon was valued at $4.2 billion; after filing for bankruptcy in August, its U.K. telemedicine business was sold for just over $600,000.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

focus

WSS

Biogen joins immunology wave with $1.15 billion acquisition of HI

Democrats decry new health bill for going easy on private equity

Reports of telehealth's death have been greatly exaggerated

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Digital health: a case of mistaken identity

Wikipedia

explore

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

Former reverend arrested for allegedly killing 8

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Fentanyl is making it harder to start addiction treatment

Affirmative action in medical school literally saved lives

Senate panel puts off hardest PBM reforms for another day

Peter Hotez and the public health issue of online harassment

Device maker Teleflex to acquire urology company for $600M

Trump demands the U.S. pay no more for drugs than other countries … again

Liver decline slowed by off

focus

Democrats decry new health bill for going easy on private equity

As a primary care physician, here's how I hope to partner with AI

Device maker Teleflex to acquire urology company for $600M

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Device maker Teleflex to acquire urology company for $600M

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

hotspot

focus

Wikipedia

focus